Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

5(62.5%)

Phase 3

2(25.0%)

Phase 2

1(12.5%)

8Total

Phase 1(5)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02414841Phase 3Completed

A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)

Role: lead

NCT02110901Phase 3Completed

A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)

Role: lead

NCT02953496Phase 1Withdrawn

Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries

Role: lead

NCT02956993Phase 1Completed

Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)

Role: lead

NCT01616290Phase 1Completed

Pilot Study of PRT-201 Following Angioplasty in Patients With Peripheral Artery Disease (PAD)

Role: lead

NCT01305824Phase 2Completed

A Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

Role: lead

NCT00679991Phase 1Completed

A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients

Role: lead

NCT01001351Phase 1Completed

A Study of PRT-201 Administered After Arteriovenous Graft (AVG) Creation in Patients With Chronic Kidney Disease

Role: lead

All 8 trials loaded